| 摘要 |
A pharmaceutical composition comprising a naphthoquinone-based compound is provided to activate NQ01(NAD(P)H:quinine oxidoreductase 1) and inhibit proliferation of vascular smooth muscle, thereby showing excellent effect on arteriosclerosis or restenosis occurring after operation for treating the same. A pharmaceutical composition for treating and preventing restenosis comprises: (a) a therapeutically effective amount of a compound represented by a formula(1), a pharmaceutically acceptable salt thereof, a solvate thereof or an isomer thereof; and (b) a pharmaceutically acceptable carrier, a diluent, or an excipient, or a combination thereof. In the formula(1), each R1 and R2 is independently H, halogen, alkoxy, hydroxy or C1-6 alkyl, or R1 and R2 may be coupled to each other to form a ring structure(wherein the ring structure is a saturated structure or a partial or a total unsaturated structure); each R3, R4, R5, R6, R7 and R8 is independently H, hydroxy, C1-20 alkyl, alkene or alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two of the R3, R4, R5, R6, R7 and R8 are coupled to each other to form a ring structure(wherein the ring structure is a saturated structure or a partial or a total unsaturated structure); X is C(R)(R'), N(R"), O or S(wherein each R, R' and R" is independently H or C1-6 alkyl); and n is 0 or 1, provided that adjacent carbon atoms thereof are directly coupled to one another to form a ring structure when n is 0. A pharmaceutical preparation comprises the pharmaceutical composition and is formulated into an oral administering intestine delivery system. To prepare a medicine for preventing and treating diseases caused by rapid increase of vascular smooth muscle cells such as restenosis, the compound of the formula(1) is used.
|
